Schouten out as Johnston made Mucosis CEO
This article was originally published in Scrip
Dutch biotech Mucosis has made Thomas Johnston CEO, succeeding Govert Schouten who has left the company to found an internet start-up. Mr Johnston joined the company as chief business officer in May 2011 having previously served as vice-president of strategy at Novavax.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.